Wiley Blackwell

SHERPA: Unknown

People

  1. Moskowitz
    Moskowitz
  2. Horwitz
    Horwitz
  3. Kumar
    Kumar
  4. Hamlin
    Hamlin
  5. Noy
    Noy
  6. Zelenetz
    Zelenetz
  7. Dogan
    Dogan
  8. Palomba
    Palomba
  9. Myskowski
    Myskowski
  10. Yahalom
    Yahalom

Groups

  1. Center for Hematologic Malignancies (31)
  2. Department of Medicine (31)
  3. Hematologic Malignancies, Division of (31)
  4. Lymphoma (31)
  5. Population Sciences Research Program (21)
  6. Department of Pathology and Laboratory Medicine (15)
  7. Hematology-Oncology Fellows (14)
  8. Sloan Kettering Institute Postdocs (13)
  9. Survivorship Research (13)
  10. Epidemiology and Biostatistics (10)
Search Within
  1. "Alison Moskowitz"
Formats
  1. Meeting Abstract (23)
  2. Journal Article (6)
  3. Research Letter (2)
Groups
  1. Center for Hematologic Malignancies (31)
  2. Department of Medicine (31)
  3. Hematologic Malignancies, Division of (31)
  4. Lymphoma (31)
  5. Population Sciences Research Program (21)
  6. Department of Pathology and Laboratory Medicine (15)

More Groups

People
  1. Alison Moskowitz (31)
  2. Steven Horwitz (21)
  3. Anita Kumar (12)
  4. David Straus (12)
  5. Andrew Zelenetz (11)
  6. Ariela Noy (11)

More People

Years
  1. 2025 (1)
  2. 2023 (2)
  3. 2022 (1)
  4. 2021 (6)
  5. 2019 (10)
  6. 2018 (2)

More Years

Publications
  1. Hematological Oncology (23)
  2. International Journal of Dermatology (2)
  3. Journal of the European Academy of Dermatology and Venereology (2)
  4. Cancer (1)
  5. Cytometry Part B—Clinical Cytometry (1)
  6. Histopathology (1)

More Publications

Results (31)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Cutaneous T-cell lymphoma and dupilumab use: A retrospective matched cohort study of clinical characteristics and treatment outcomes
    Research Letter

    Stuver, R.; Dusza, S.; Epstein-Peterson, Z. D.; Ghione, P.; Horwitz, S. M.; Johnson, W.; Moskowitz, A. J.; Myskowski, P.; Pulitzer, M.; Geller, S.
    Journal of the European Academy of Dermatology and Venereology (2025)

    Fulltext@MSK | Save
  • PET‐adapted therapy with nivolumab plus adriamycin, vinblastine, and dacarbazine for newly diagnosed stage III or IV Hodgkin Lymphoma
    Meeting Abstract

    Moskowitz, A.; Savage, K.; Feldman, T.; Ganesan, N.; Hancock, H.; Davey, T.; Perez, L.; Santarosa, A.; Subzwari, S.; Capadona, C.; more...
    Hematological Oncology (2023)

    Fulltext@MSK | Save
  • Phase 2 trial of nivolumab plus adriamycin, vinblastine, dacarbazine (N‐AVD) as frontline therapy in older adults with Hodgkin lymphoma
    Meeting Abstract

    Torka, P.; Feldman, T.; Savage, K.; Ganesan, N.; Hancock, H.; Davey, T.; Perez, L.; Santarosa, A.; Subzwari, S.; Capadona, C.; more...
    Hematological Oncology (2023)

    Fulltext@MSK | Save
  • PD-1 improves accurate detection of Sezary cells by flow cytometry in peripheral blood in mycosis fungoides/Sezary syndrome
    Journal Article

    Lewis, N. E.; Gao, Q.; Petrova-Drus, K.; Pulitzer, M.; Sigler, A.; Baik, J.; Moskowitz, A. J.; Horwitz, S. M.; Dogan, A.; Roshal, M.
    Cytometry Part B—Clinical Cytometry (2022)

    Fulltext@MSK | Save
  • Predictive value of quantitative (18)F‐FDG‐PET‐CT radiomics analysis in 174 patients with relapsed/refractory classical Hodgkin lymphoma
    Meeting Abstract

    Driessen, J.; Zwezerijnen, G. J. C.; Schöder, H.; Moskowitz, A. J.; Kersten, M. J.; Moskowitz, C. H.; Eertink, J. J.; van de Brug, T.; de Vet, H. C. W.; Hoekstra, O. S.; more...
    Hematological Oncology (2021)

    Fulltext@MSK | Save
  • Nivolumab plus brentuximab vedotin for relapsed/refractory primary mediastinal large B‐cell lymphoma: Extended follow‐up from the phase 2 CheckMate 436 study
    Meeting Abstract

    Zinzani, P. L.; Santoro, A.; Gritti, G.; Brice, P.; Barr, P. M.; Kuruvilla, J.; Cunningham, D.; Kline, J.; Johnson, N. A.; Mehta‐Shah, N.; more...
    Hematological Oncology (2021)

    Fulltext@MSK | Save
  • A phase II trial of reduced dose brentuximab vedotin for cutaneous T‐cell lymphomas
    Meeting Abstract

    Khan, N.; Noor, S.; Geller, S.; Khodadoust, M. S.; Kheterpal, M.; Hancock, H.; Davey, T.; Ryu, S.; Perez, L.; Lares, A.; more...
    Hematological Oncology (2021)

    Fulltext@MSK | Save
  • The combination of duvelisib and romidepsin (DR) is highly active against relapsed/refractory peripheral T‐cell lymphoma with low rates of transaminitis: Final results
    Meeting Abstract

    Horwitz, S. M.; Moskowitz, A. J.; Mehta‐Shah, N.; Jacobsen, E. D.; Khodadoust, M. S.; Ganesan, N.; Drill, E.; Hancock, H.; Davey, T.; Myskowski, P.; more...
    Hematological Oncology (2021)

    Fulltext@MSK | Save
  • Clinical outcomes and the role of observation in early‐stage follicular lymphoma
    Meeting Abstract

    Sha, F.; Okwali, M.; Alperovich, A.; Caron, P. C.; Falchi, L.; Hamilton, A.; Hamlin, P. A.; Horwitz, S. M.; Joffe, E.; Kumar, A.; more...
    Hematological Oncology (2021)

    Fulltext@MSK | Save
  • Clinical characteristics and outcomes of adult lymphoma‐associated hemophagocytic lymphohistiocytosis (HLH)
    Meeting Abstract

    Lee, C. Y.; Wills Sanin, B.; Vardhana, S. A.; Moskowitz, A. J.
    Hematological Oncology (2021)

    Fulltext@MSK | Save